Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 13Spondylitis, Ankylosing 5Colitis, Ulcerative 4Psoriasis 3Crohn Disease 3Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Spondylarthritis 1Sarcoidosis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammatory Bowel Diseases 1Inflammation 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1Autoimmune Diseases 1

Interventions

pimodivir 1Sunitinib 1Rosuvastatin Calcium 1Olive Oil 1Midazolam 1Cyclosporine 1Control Groups 1Adalimumab 1(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Healthy × Adalimumab × Clear all
NCT02912247 2019-03-07

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
183 enrolled

Healthy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡